Liposic (Carbomer)

Liposic, containing carbomer, acts as a viscosity enhancer in ophthalmic formulations, supporting better drug delivery and patient comfort.

• Dry eye syndrome: improves tear film stability by increasing drop viscosity.
• Post‑operative ocular inflammation: prolongs residence time of administered drops, aiding anti‑inflammatory effect.
• Contact lens discomfort: enhances lubricating eye drops for sustained comfort while wearing lenses.

• Carbomer is a high‑molecular‑weight polymer that swells in aqueous media and forms a three‑dimensional gel matrix. This network traps water molecules, markedly increasing the viscosity of ophthalmic solutions. The resulting gel slows drainage from the ocular surface, allowing active agents to remain in contact with the eye for a longer period, thereby enhancing drug absorption and therapeutic effect.

Liposic may cause local ocular reactions, although it is generally well tolerated.

Common Side Effects

• Transient blurred vision: temporary visual disturbance after instillation.
• Mild ocular irritation: stinging or burning sensation.
• Redness of the conjunctiva: mild hyperemia.
• Foreign body sensation: feeling of grit in the eye.
• Temporary tearing: increased lacrimation.

Serious or Rare Side Effects

• Allergic reaction: swelling, itching, or rash around the eye.
• Severe conjunctivitis: marked inflammation and discharge.
• Corneal edema: swelling of the cornea affecting vision.
• Persistent ocular pain: lasting discomfort beyond initial application.

When using Liposic, consider the following safety measures.

• Allergy assessment: verify patient has no known hypersensitivity to carbomer or related polymers.
• Contact lens use: remove lenses before instillation to avoid trapping the gel.
• Sterile handling: use aseptic technique to prevent contamination of the solution.
• Concurrent ocular medications: avoid mixing with incompatible preservatives.
• Store below 25°C: keep in the original container, protect from light and moisture.

Liposic may interact with certain ophthalmic agents; awareness of these interactions helps maintain formulation stability.

Major Interactions (Avoid)

• Incompatible preservatives: may precipitate when combined with high concentrations of benzalkonium chloride.
• pH‑sensitive drugs: can alter stability of drugs requiring specific pH ranges.

Moderate Interactions (Monitor Closely)

• Other viscosity agents: concurrent use may excessively increase solution thickness, causing blurred vision.
• Antiglaucoma medications: altered viscosity may affect drug absorption and intra‑ocular pressure control.
• Anesthetic eye drops: may enhance corneal penetration, requiring monitoring.